RNAi to treat SARS‐CoV‐2—variant proofing the next generation of therapies
There is an urgent need to bring new antivirals to SARS‐CoV‐2 to the market. Indeed, in the last 3 months, we have seen at least two new antivirals approved, molnupiravir and paxlovid. Both are older established antivirals that show some efficacy against SARS‐CoV‐2. The work by Chang et al (2022) in the current issue of EMBO Molecular Medicine explores the use of short interfering RNAs to directly target SARS‐CoV‐2 and shows that RNAi is an effective approach to reducing, or even eliminating viral replication, depending on the experimental setting. This antiviral effect results in significant prevention of infection‐related pathology in animals. The key feature of this approach, besides its simplicity as naked siRNAs, is that all current variants are covered by this treatment.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
RNAi to treat SARS‐CoV‐2—variant proofing the next generation of therapies ; day:14 ; month:03 ; year:2022 ; extent:3
EMBO molecular medicine / European Molecular Biology Organization ; (14.03.2022) (gesamt 3)
- Urheber
-
McMillan, Nigel A. J.
Morris, Kevin V.
Idris, Adi
- DOI
-
10.15252/emmm.202215811
- URN
-
urn:nbn:de:101:1-2022032606575395335780
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- McMillan, Nigel A. J.
- Morris, Kevin V.
- Idris, Adi
Ähnliche Objekte (12)
Novel RNAi-Based Therapies for Atherosclerosis
Gene Therapies in Clinical Development to Treat Retinal Disorders
New therapies to treat inherited cardiomyopathies are on the way
Facial diplegia with hyperreflexia-a mild Guillain-Barre Syndrome variant, to treat or not to treat?
Brief review: cell replacement therapies to treat type 1 diabetes mellitus
Next-generation in vivo models for improved pancreatic cancer therapies
Nymphal RNAi: systemic RNAi mediated gene knockdown in juvenile grasshopper
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Programmable synthetic receptors: the next-generation of cell and gene therapies
Next-generation sequencing algorithms : from read mapping to variant detection
Next-generation sequencing algorithms : from read mapping to variant detection
Multiplex in vitro and in vivo RNAi screening to identify treatment response modifiers of targeted therapies in HCC
Novel RNAi-Based Therapies for Atherosclerosis
Gene Therapies in Clinical Development to Treat Retinal Disorders
New therapies to treat inherited cardiomyopathies are on the way
Facial diplegia with hyperreflexia-a mild Guillain-Barre Syndrome variant, to treat or not to treat?
Brief review: cell replacement therapies to treat type 1 diabetes mellitus
Next-generation in vivo models for improved pancreatic cancer therapies
Nymphal RNAi: systemic RNAi mediated gene knockdown in juvenile grasshopper
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Programmable synthetic receptors: the next-generation of cell and gene therapies
Next-generation sequencing algorithms : from read mapping to variant detection
Next-generation sequencing algorithms : from read mapping to variant detection
Multiplex in vitro and in vivo RNAi screening to identify treatment response modifiers of targeted therapies in HCC
Novel RNAi-Based Therapies for Atherosclerosis
Gene Therapies in Clinical Development to Treat Retinal Disorders
New therapies to treat inherited cardiomyopathies are on the way
Facial diplegia with hyperreflexia-a mild Guillain-Barre Syndrome variant, to treat or not to treat?
Brief review: cell replacement therapies to treat type 1 diabetes mellitus
Next-generation in vivo models for improved pancreatic cancer therapies
Nymphal RNAi: systemic RNAi mediated gene knockdown in juvenile grasshopper
Hyperlipidaemia in diabetes: are there particular considerations for next-generation therapies?
Programmable synthetic receptors: the next-generation of cell and gene therapies
Next-generation sequencing algorithms : from read mapping to variant detection
Next-generation sequencing algorithms : from read mapping to variant detection